Outcomes of adult medulloblastoma treated with a multimodality approach: A tertiary cancer center experience
Open Access
- 1 October 2015
- journal article
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 04 (04) , 174-178
Abstract
Objectives: Adult medulloblastoma (AMB) is a rare central nervous system tumor. We aimed to analyze the treatment outcomes of AMB treated at our institute with surgery followed by craniospinal irradiation (CSI) and adjuvant chemotherapy. Methods: We retrospectively evaluated the treatment charts of 31 patients of AMB treated from 2003-2011. The patient demography, treatment details and survival data were collected in a predesigned proforma. Kaplan Meier method was used to analyze disease free survival (DFS) and the impact of prognostic factors was determined by univariate analysis (log rank test). Results: Male: Female ratio was 21:10. Cerebrospinal fluid dissemination was noted in 16% cases. CSI (36 Gray at 1.8 Gray/fraction to entire neuraxis and 20 Gray at 2 Gray/fraction boost to posterior fossa) was used in all cases. 26 patients received adjuvant chemotherapy (carboplatin plus etoposide). Median follows up was 26.85 months (9.47-119.73 months). The estimated 3 and 5 years DFS was found to be 84.9% and 50.7% respectively. On univariate analysis, tumor located laterally had a trend towards better DFS (HR 3.04; 95%CI 0.722 to 12.812; P = 0.07) compared to midline tumors. Other factors like adjuvant chemotherapy, age, gender, surgical extent had no statistically significant impact on survival. Conclusion: The results of our study (largest series from India) show that the regimen of surgery, adjuvant CSI and chemotherapy is feasible and confers descent survival. AMB patients should be treated with a multimodality approach in a tertiary care centre.Keywords
This publication has 26 references indexed in Scilit:
- Adult Medulloblastoma Comprises Three Major Molecular VariantsJournal of Clinical Oncology, 2011
- Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET)Critical Reviews in Oncology/Hematology, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2006
- Survival of adults treated for medulloblastoma using paediatric protocolsEuropean Journal of Cancer, 2005
- Survival and recurrence factors in adult medulloblastoma: The M.D. Anderson Cancer Center experience from 1978 to 1998Neuro-Oncology, 2001
- Survival and recurrence factors in adult medulloblastoma: The M.D. Anderson Cancer Center experience from 1978 to 1998Neuro-Oncology, 2001
- Adult Medulloblastoma: Prognostic Factors and Patterns of RelapseNeurosurgery, 2000
- Survival results in adult patients treated for medulloblastomaCancer, 1992
- Medulloblastoma in adults: A review of 47 patients treated between 1952 and 1981International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1990